Table 2.
Estimating the appropriateness of empiric antibiotic prescriptions for community-acquired pneumonia (CAP) in patients subsequently diagnosed with Legionnaires’ disease (CALD)
| Total | |
|---|---|
| Empiric CAP therapy prior to confirmed CALD-diagnosis | n= 195 |
| Empiric CAP treatment prescribed (%) | 137 (70.3) |
| No empiric CAP treatment prescribed (%) | 58 (29.7) |
| Empiric CAP treatment prescribed (%)† | n = 137 |
| Any empiric CAP treatment with Legionella spp. coverage* | 107 (78.1) |
| Monotherapy with amoxicillin/clavulanic acid | 15 (10.9) |
| Monotherapy with ceftriaxone | 5 (3.6) |
| Monotherapy with quinolone | 12 (8.8) |
| Monotherapy with macrolide | 6 (4.4) |
| Monotherapy with doxycycline | 0 (0.0) |
| Combination therapy with ceftriaxone plus macrolides | 21 (15.3) |
| Combination therapy with amoxicillin/clavulanic acid plus macrolides | 48 (35.0) |
| Treatment with cefepime or piperacillin/tazobactam | 19 (13.9) |
| Prescribed empiric CAP treatment supported by guidelines (%) | n = 137 |
| Supported | 81 (59.1) |
| Dose too low | 26 (19.0) |
| Spectrum too broad | 22 (16.1) |
| Spectrum too narrow | 6 (4.4) |
| Insufficient data to estimate appropriateness | 2 (1.5) |
†percentages do not add up to 100%, as sometimes two categories apply
*includes all mono and combination therapies with macrolides, quinolones and doxycycline